Bidirectional Mendelian Randomization Analysis Reveals Protective Effects of Bioavailable Testosterone Against Hypertensive Disorders of Pregnancy
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpaf208 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Hua Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Testosterone, Hypertension, Pregnancy-Induced. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Shaanxi Province.
Abstract (Originalsprache)
Background
Hypertensive disorders of pregnancy (HDP) substantially increase maternal and fetal morbidity and mortality. Although reduced circulating bioavailable testosterone (BT) has been observed in women with HDP, the causal relationship and underlying mechanisms remain unresolved. Based on previous clinical and experimental evidence, we hypothesized a potential causal relationship between BT levels and HDP, with subsequent analyses designed to explore the possible metabolic and anti-inflammatory pathways involved.
Methods
Summary statistics for BT and HDP were obtained from the Integrative Epidemiology Unit OpenGWAS database. A 2-sample Mendelian randomization (MR) framework was implemented to evaluate causality, complemented by extensive sensitivity analyses to strengthen robustness. To explore potential mechanisms, expression quantitative trait loci integration, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes enrichment, and protein-protein interaction (PPI) network analyses were performed.
Results
Mendelian randomization analyses provided evidence of a protective causal effect of BT on HDP (inverse variance weighted OR = 0.81; 95% confidential interval, 0.68-0.97; P = .023), with no indication of reverse causality. Sensitivity tests consistently confirmed the reliability of these findings. Genes associated with BT-related single nucleotide polymorphisms were enriched in metabolic and immune pathways, notably the NOD-like receptor and interleukin-17 (IL-17) pathways. Within the PPI network, nuclear factor kappa B inhibitor alpha (NFKBIA) emerged as a pivotal regulator of nuclear factor kappa B (NF-κB) signaling, thereby supporting a role for testosterone-mediated modulation of inflammation in HDP protection.
Conclusion
From a genetic standpoint, BT appears to act as a protective factor against HDP, potentially safeguarding cardiovascular function through interconnected metabolic and anti-inflammatory mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Pathology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Neonatology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Hua Zhang
Förderung
- Natural Science Foundation of Shaanxi Province
Zitieren
APA
Zhang, H., Chen, Q., Ding, P., Chang, Y., Cheng, D., & Li, M. (2025). Bidirectional Mendelian Randomization Analysis Reveals Protective Effects of Bioavailable Testosterone Against Hypertensive Disorders of Pregnancy. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf208
Vancouver
Zhang H, Chen Q, Ding P, Chang Y, Cheng D, Li M. Bidirectional Mendelian Randomization Analysis Reveals Protective Effects of Bioavailable Testosterone Against Hypertensive Disorders of Pregnancy. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf208
BibTeX
@article{Zhang2025,
author = {Zhang, Hua and Chen, Qing and Ding, Pan and Chang, Yinan and Cheng, Dong and Li, Mu},
title = {Bidirectional Mendelian Randomization Analysis Reveals Protective Effects of Bioavailable Testosterone Against Hypertensive Disorders of Pregnancy},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpaf208}
}
EUVIMED